Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 2,482 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Richard A. Graham sold 2,482 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $9.89, for a total transaction of $24,546.98. Following the completion of the transaction, the senior vice president now directly owns 336,803 shares of the company’s stock, valued at $3,330,981.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Theravance Biopharma Stock Down 1.6 %

TBPH stock opened at $8.86 on Tuesday. Theravance Biopharma, Inc. has a twelve month low of $8.85 and a twelve month high of $12.03. The business’s fifty day moving average is $9.72 and its 200-day moving average is $10.45. The company has a market cap of $467.90 million, a P/E ratio of 0.78 and a beta of 0.43.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $13.75 million for the quarter, compared to analyst estimates of $15.24 million. Theravance Biopharma had a net margin of 1,694.17% and a negative return on equity of 16.88%. Research analysts anticipate that Theravance Biopharma, Inc. will post -1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. acquired a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $101,000. Acadian Asset Management LLC boosted its position in Theravance Biopharma by 51.6% during the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,818 shares during the last quarter. Vanguard Group Inc. boosted its position in Theravance Biopharma by 10.3% during the first quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock valued at $66,421,000 after purchasing an additional 648,124 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Theravance Biopharma by 3.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock valued at $3,850,000 after purchasing an additional 12,095 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Theravance Biopharma by 45.0% during the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on TBPH shares. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, August 8th. StockNews.com started coverage on Theravance Biopharma in a research note on Thursday, August 17th. They set a “hold” rating on the stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.